YaoGeJu

Public drug landscapesDrug landscape

Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation

As of 13 November 2026, for Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation, 12 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 0 holders.

Companies, stages and changes, with each record available on this page.

Listed in the US FDA Orange Book as ADVAIR DISKUS 100/50 (NDA 021077, GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE).

Follow for free
Complete CDE snapshot
2026/11/13 06:42
Matching scope
Same generic name; dosage forms and combinations kept separate

US Orange Book listing

The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.

Orange Book source export date: 2026/11/06. Version: 2026-11-06.

Showing 5 of 6 distinct brand names.

A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.

Verified official English dosage form: Powder for Inhalation. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.

Same dosage form

Brand nameApplicant (source text)Application numberDosage form (source text)Route (source text)Marketing status (source text)Approval date
ADVAIR DISKUS 100/50 GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE NDA 021077 · Product no. 001 POWDER INHALATION HUMAN PRESCRIPTION DRUG 2000/08/24
ADVAIR DISKUS 250/50 GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE NDA 021077 · Product no. 002 POWDER INHALATION HUMAN PRESCRIPTION DRUG 2000/08/24
ADVAIR DISKUS 500/50 GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE NDA 021077 · Product no. 003 POWDER INHALATION HUMAN PRESCRIPTION DRUG 2000/08/24
AIRDUO RESPICLICK TEVA PHARMACEUTICAL INDUSTRIES LTD NDA 208799 · Product no. 001, 002, 003 POWDER INHALATION HUMAN PRESCRIPTION DRUG 2017/01/27
AIRDUO DIGIHALER TEVA PHARMACEUTICAL INDUSTRIES LTD NDA 208799 · Product no. 004, 005, 006 POWDER INHALATION DISCONTINUED 2019/07/12

Other dosage forms of the same ingredient

No listings in this group among the displayed brand names.

Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.

Ingredient cross-list details ↗

Which companies are listed, and at what stages?

Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.

Chemical-drug catalogue

Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.

Marketing authorization holderManufacturerApproval numberApprovedStrength / specificationCatalogue category (source text)View source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

NHSA drug codes

Loaded records: 11 distinct approval numbers and 6 companies.

Company / applicantApproval numberStrength / specificationNHSA classNHSA drug codeView source
Laboratoire GlaxoSmithKline国药准字HJ20150323See sourceCategory BXR03AKS054L031010178564NHSA
M/s. Cipla Limited国药准字HJ20250075See sourceCategory BXR03AKS054L031010179537NHSA
Sichuan Pu Rui Te Pharma Co., Ltd. romanized国药准字H20253521See sourceCategory BXR03AKS054L031010181590NHSA
Health Yuan Pharma Group Co., Ltd. romanized国药准字H20243906See sourceCategory BXR03AKS054L031010183037NHSA
Shanghai Ou Mi Ni Pharmaceuticals Technology Co., Ltd. romanized国药准字H20255235See sourceCategory BXR03AKS054L031010185001NHSA
Neutec Ilac San. Tic. A.S.国药准字HJ20240136See sourceCategory BXR03AKS054L031010185370NHSA
Laboratoire GlaxoSmithKline国药准字HJ20150324See sourceCategory BXR03AKS054L031010278564NHSA
Laboratoire GlaxoSmithKline国药准字HJ20150325See sourceCategory BXR03AKS054L031020178564NHSA
M/s. Cipla Limited国药准字HJ20250076See sourceCategory BXR03AKS054L031020179537NHSA
Neutec Ilac San. Tic. A.S.国药准字HJ20240137See sourceCategory BXR03AKS054L031020185370NHSA
Laboratoire GlaxoSmithKline国药准字HJ20150323See sourceCategory BXR03AKS054L031020278564NHSA
Laboratoire GlaxoSmithKline国药准字HJ20150324See sourceCategory BXR03AKS054L031020378564NHSA
Laboratoire GlaxoSmithKline国药准字HJ20150325See sourceCategory BXR03AKS054L031020478564NHSA
M/s. Cipla Limited国药准字HJ20250077See sourceCategory BXR03AKS054L031030179537NHSA

Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.

Current under-review applications

Loaded records: 12 filings and 5 distinct first applicants.

Generic 3 · Import 2 · Supplement 7

Current under-review applications
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Bo Rui Pharmaceutical (Suzhou) Co., Ltd. romanizedCYHS2600253Generic2026/01/22Not stated by sourceCDE
Bo Rui Pharmaceutical (Suzhou) Co., Ltd. romanizedCYHS2600252Generic2026/01/22Not stated by sourceCDE
Celon Pharma S.A.; Jiangsu Simcere Pharmaceutical Co. Ltd.JYHS2400054Import2024/10/30Not stated by sourceCDE
Celon Pharma S.A.; Jiangsu Simcere Pharmaceutical Co. Ltd.JYHS2400053Import2024/10/30Not stated by sourceCDE
Run Sheng Pharma Co., Ltd. romanizedCYHS2602496Generic2026/10/12Not stated by sourceCDE
Laboratoire GlaxoSmithKline; Glaxo Wellcome ProductionJYHB2600460Supplement2026/08/12Not stated by sourceCDE
Laboratoire GlaxoSmithKline; Glaxo Wellcome ProductionJYHB2600459Supplement2026/08/12Not stated by sourceCDE
Laboratoire GlaxoSmithKline; Glaxo Wellcome ProductionJYHB2600458Supplement2026/08/12Not stated by sourceCDE
Sichuan Pu Rui Te Pharma Co., Ltd. romanizedCYHB2600789Supplement2026/04/22Not stated by sourceCDE
Laboratoire GlaxoSmithKline; Glaxo Wellcome ProductionJYHB2500545Supplement2025/10/17Not stated by sourceCDE
Laboratoire GlaxoSmithKline; Glaxo Wellcome ProductionJYHB2500544Supplement2025/10/17Not stated by sourceCDE
Laboratoire GlaxoSmithKline; Glaxo Wellcome ProductionJYHB2500543Supplement2025/10/17Not stated by sourceCDE
New generic filings in 2026

Loaded records: 3 filings and 2 distinct first applicants.

New generic filings in 2026
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Bo Rui Pharmaceutical (Suzhou) Co., Ltd. romanizedCYHS2600253Generic2026/01/22Not stated by sourceCDE
Bo Rui Pharmaceutical (Suzhou) Co., Ltd. romanizedCYHS2600252Generic2026/01/22Not stated by sourceCDE
Run Sheng Pharma Co., Ltd. romanizedCYHS2602496Generic2026/10/12Not stated by sourceCDE
API registrations

Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.

NameCompany / applicantRegistration numberStatusName matchSource update dateView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.

What changed recently?

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.

Trial registration does not mean an application will follow.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

  1. 2026/10/23No longer listed under review

    Sichuan Pu Rui Te Pharma Co., Ltd. romanized

    CYHB2600788

    Fact date: 2026/10/23 · Site observation date: 2026/10/23

    Accepted: 2026/04/22

    not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/21); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 12

    NMPA · Table row 12 ↗ View source ↗
  2. 2026/10/21Supplement delivery

    Sichuan Pu Rui Te Pharma Co., Ltd. romanized

    CYHB2600788

    Fact date: 2026/10/21 · Publication date: 2026/10/23 · Site observation date: 2026/11/03

    Supplemental application; excluded from new marketing approvals.

    View source · Table row 12 ↗
  3. 2026/10/12Accepted

    Run Sheng Pharma Co., Ltd. romanized

    CYHS2602496

    Fact date: 2026/10/12 · Site observation date: 2026/10/22

    View source ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

Full API register
Last successful update: 2026/11/13 06:41
NHSA drug codes
Last successful update: 2026/11/05 06:45

The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.

NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Drug Clinical Trial Registry and Information Disclosure Platform
Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete

Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.

Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Free follow

Follow changes to Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation

Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.

Confirmation links expire in 7 days. No digest is sent before confirmation; existing follows are not duplicated.

Sign in to choose products